BioMarin Pharmaceutical | BMRN - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amgen USD 3.83B 130M 2026-03
Bayer EUR 3.53B 2.42B 2026-03
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
Incyte USD 324.17M 59.7M 2026-03
Insmed USD -200.28M 49.43M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
Moderna USD -1.39B 531M 2026-03
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 1.5B 2.29B 2025-12
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
United Therapeutics USD 325.8M 340.4M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03